Studies & Results
BCIRG 007
A multicenter phase III randomized trial comparing docetaxel (Taxotere) and trastuzumab (Herceptin) with docetaxel (Taxotere), platinum salt (cisplatin or carboplatin) and trastuzumab (Herceptin) as first line chemotherapy for patients with advanced breast cancer containing the HER2neu alteration
View FDA Study
Presentations
ASCO Annual Meeting, 2007
Pegram M, Forbes JF, Pienkowski T, et al
First overall survival analysis of a multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab as first line chemotherapy for patients with metastatic breast cancer containing the Her2/ neu alteration.
ASCO Annual Meeting, 2007
Valero V, Roche H, Pienkowski T, et al
Serum HER 2 levels in women with metastatic HER 2 - amplified Breast Cancer.
ASCO Annual Meeting, 2006
Forbes JF, Pienkowski T, Valero V, et al
A multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab first line chemotherapy for patients with metastatic breast cancer containing the Her2neu alteration.
ASCO Annual Meeting, 2006
Forbes JF, Pienkowski T, Valero V, et al: BCIRG 007
Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer.
Publications
Press MF, Sauter G, Buyse M, et al.: HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
J Clin Oncol JCO.2016.66.6693, 2016
Valero V, Forbes J, Pegram M, et al.: Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens
J Clin Oncol 29:149-156, 2011
Nabholtz J-M, Reese DM, Lindsay M-A, et al: HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Clin Breast Cancer 3 Suppl 2:S75–79, 2002
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
ASCO Annual Meeting, 2007
Pegram M, Forbes JF, Pienkowski T, et al
First overall survival analysis of a multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab as first line chemotherapy for patients with metastatic breast cancer containing the Her2/ neu alteration.
ASCO Annual Meeting, 2007
Valero V, Roche H, Pienkowski T, et al
Serum HER 2 levels in women with metastatic HER 2 - amplified Breast Cancer.
ASCO Annual Meeting, 2006
Forbes JF, Pienkowski T, Valero V, et al
A multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab first line chemotherapy for patients with metastatic breast cancer containing the Her2neu alteration.
ASCO Annual Meeting, 2006
Forbes JF, Pienkowski T, Valero V, et al: BCIRG 007
Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer.
Publications
Press MF, Sauter G, Buyse M, et al.: HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol JCO.2016.66.6693, 2016
Valero V, Forbes J, Pegram M, et al.: Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens J Clin Oncol 29:149-156, 2011
Nabholtz J-M, Reese DM, Lindsay M-A, et al: HER2-positive breast cancer: update on Breast Cancer International Research Group trials. Clin Breast Cancer 3 Suppl 2:S75–79, 2002
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org